MedTrace Logo

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

NCT00130702 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-05-01

No results posted yet for this study

Summary

The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.

Conditions

  • Myelogenous Leukemia, Acute

Interventions

DRUG

gefitinib

gefitinib (Iressa) at a dose of 750 mg, once per day

Sponsors & Collaborators

Principal Investigators

  • Daniel J DeAngelo, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130702 on ClinicalTrials.gov